Exelixis Clinical Site #81

Milan 20141

1 studies enrolling now · 2 studies all time

What they study most

Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer (CRC), Drug-Drug Interaction (DDI), Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Solid Tumor, Urothelial Carcinoma (UC)

Studies at this site

• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors — Recruiting now
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Running, not enrolling